MSD announces presentation of data on investigational use of pembrolizumab in advanced bladder cancer

MSD, known as Merck in the United States and Canada, announced the first presentation of data on the investigational use of pembrolizumab – the company’s anti-PD-1 therapy – in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). The early findings presented showed a confirmed overall response rate of 24 percent with pembrolizumab as monotherapy, as measured by RECIST v1.1, central review (n= 7/29: 95% CI, 10.3-43.5) including a complete response rate of 10 percent (3/29).
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Industry News Oncology bladder cancer Latest News pembrolizumab safety data Source Type: news